Abstract
A 78-year-old male patient with follicular carcinoma in the left thyroidal lobe with 10 cm diameter received radioiodine ablation treatment (RAT) with 5550 MBq (150 mCi) iodine-131 (131I) 2 months after the operation. During the RAT, the serum thyroglobulin (Tg) level was measured as 252.59 ng/ml. Radioiodine uptake in the thyroid bed and thoracal and pelvic regions was observed on a postablative whole-body scintigraphy. Simultaneous bone scintigraphy was performed. A moderately increased uptake was observed in the right iliac bone. Thoracal and pelvic computed tomographies (CTs) were also performed for further evaluation of the radioiodine uptake in thoracal and pelvic regions. A pathologic soft tissue lesion of 2.5 × 1.5 cm that may have been compatible with a lymphadenopathy on the anterior mediastinum was observed, and a sclerotic bone lesion of 2 cm in diameter that was concordant with metastasis on the right iliac bone was reported on CT. The patient was followed up for 5 years under suppressive dose of LT4 treatment. Serum Tg measurements and pelvic CT and/or MRI were performed periodically. Biochemical and radiological stabilization were detected during the 5-year follow-up period. Additional surgery or local therapy for the bone metastasis was not applied because of the asymptomatic and stable local metastatic disease.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803.
Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892–9.
Schlumberger M, Baudin E. Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol. 1998;138:249–52.
Robbins RJ, Srivastava S, Shaha A, Ghossein R, Larson SM, Fleisher M, et al. Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. J Clin Endocrinol Metab. 2004;89:6010–6.
Bernier MO, Leenhardt L, Hoang C, Aurengo A, Mary JY, Menegaux F, et al. Survival and therapeutic modalities in patients with bone metastasis of differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2001;86:1568–73.
Farooki A, Leung V, Tala H, Tuttle RM. Skeletal-related events due to bone metastases from differentiated thyroid cancer. J Clin Endocrinol Metab. 2012;97:2433–9.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2015;26:1–133. https://doi.org/10.1089/thy.2015.0020.
NCCN Clinical Practice Guidelines in Oncology, Thyroid Carcinoma, 2015 Version 2. 2015. NCCN.org.
Schlumberger M, Brose M, Elisei R, Leboulleux S, Luster M, Pitoia F, Pacini F. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2014;2:356–8. https://doi.org/10.1016/S2213-8587(13)70215-8.
Ito Y, Suzuki S, Ito K, Imai T, Okamoto T, Kitano H, et al. Tyrosine-kinase inhibitors to treat radioiodine-refracted, metastatic, or recurred and progressive differentiated thyroid carcinoma. Endocr J. 2016;63:597–602. https://doi.org/10.1507/endocrj.EJ16-0064.
Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 2007;246:466–70.
Vasko V, Espinosa AV, Scouten W, He H, Auer H, Liyanarachchi S, et al. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci. 2007;104(8):2803.
Elboğa U, Özkaya M, Sayiner ZA, Çelen YZ. Lu-177 labelled peptide treatment for radioiodine-refractory differentiated thyroid carcinoma. BMJ Case Rep. 2016. https://doi.org/10.1136/bcr-2015-213627.
Santhanam P, Taieb D, Solnes L, Marashdeh W, Ladenson PW. Utility of I-124 PET/CT in identifying radioiodine avid lesions in differentiated thyroid cancer: a systematic review and meta-analysis. Clin Endocrinol. 2017;86:645–51. https://doi.org/10.1111/cen.13306.
Dercle L, Deandreis D, Terroir M, Leboulleux S, Lumbroso J, Schlumberger M. Evaluation of (124)I PET/CT and (124)I PET/MRI in the management of patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2016;43:1006–10.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Özkan, E., Soydal, Ç. (2019). Follicular Thyroid Cancer and Bone Metastasis. In: Özülker, T., Adaş, M., Günay, S. (eds) Thyroid and Parathyroid Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-78476-2_50
Download citation
DOI: https://doi.org/10.1007/978-3-319-78476-2_50
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-78475-5
Online ISBN: 978-3-319-78476-2
eBook Packages: MedicineMedicine (R0)